Showing 2951 results
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Event /
-
Press release /
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED…
Pagination
- ‹ Previous page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- …
- 296
- › Next page